- Planned Cohort of 21 Patients with Non-Small Cell Lung Cancer Enrolled in First Stage of Trial Assessing Regimen of Bavituximab with Carboplatin and
TUSTIN, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for cancer and serious viral infections, today announced that it has completed enrollment in the first stage of its Phase II trial evaluating a combination regimen of bavituximab with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). The primary objective of the study is to assess the overall tumor response rate in patients receiving the combination therapy.
Peregrine president and CEO Steven W. King noted, "The rapid completion of enrollment in the first stage of this study adds to the positive momentum we have built in our bavituximab clinical program. We look forward to reporting initial data from this trial as patient treatment and follow-up continue and to learning more about bavituximab's potential as a novel targeted therapy for this devastating disease."
In the trial's Simon two-stage design, 21 patients with NSCLC have been
enrolled in Stage A of the study. The trial may be expanded to include up
to a total of 49 patients if promising results are observed in the initial
cohort. Secondary objectives of the study include assessing time to tumor
progression, duration of response, overall patient survival and safety
parameters. Patients are receiving bavituximab and up to six cycles of
carboplatin and paclitaxel, and they may continue to receive bavituximab as
long as the cancer does not progress and side effects are acce
|SOURCE Peregrine Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved